 Pyrimidinones
"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.
| Descriptor ID |
D011744
|
| MeSH Number(s) |
D03.383.742.698
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".
This graph shows the total number of publications written about "Pyrimidinones" by people in this website by year, and whether "Pyrimidinones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 2 | 1 | 3 | | 2013 | 0 | 3 | 3 | | 2014 | 1 | 5 | 6 | | 2015 | 3 | 3 | 6 | | 2016 | 0 | 3 | 3 | | 2017 | 2 | 4 | 6 | | 2018 | 3 | 3 | 6 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 2 | 4 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 2 | 2 | | 2023 | 1 | 3 | 4 | | 2024 | 2 | 1 | 3 | | 2025 | 3 | 1 | 4 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Hollis RL, Miller A, Lankes HA, Wong KK, Rodgers W, Millan D, Carty K, Coleman RL, Moore KN, Alvarez Secord A, O'Malley DM, Chan JK, Hagemann AR, Gaillard S, Guntupalli SR, Edelson MI, Rose PG, Dorigo O, Banerjee S, Ewing A, Churchman M, Sood AK, Herrington CS, Gourley C, Gershenson DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res. 2026 Feb 17; 32(4):724-734.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Roy SF, Agim NG, Mir A, Couts KL, Vandergriff T, Robinson WA, Bastian BC, Frieden IJ, Yeh I. Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. Br J Dermatol. 2025 07 17; 193(2):232-239.
-
Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, González Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. J Clin Oncol. 2025 Sep 10; 43(26):2897-2907.
-
Liu J, Edwards Mayhew RG, Imbornoni LM, Jung JL, Oliver SCN, Foreman NK, Mulcahy Levy JM, Hemenway M, McCourt EA. Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases. J AAPOS. 2025 Apr; 29(2):104178.
-
Wu J, Wang J, O'Connor TN, Tzetzo SL, Gurova KV, Knudsen ES, Witkiewicz AK. Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models. Mol Cancer Ther. 2024 Dec 03; 23(12):1801-1814.
-
Wu A, Yan J, Su T, Feng C, Long X, Pan Y, Ye R, Xia T, Long H, Wu J, Xiao X. Trametinib boosts palbociclib's efficacy in breast cancer via autophagy inhibition. Oncol Res. 2024; 32(7):1197-1207.
-
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
-
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023 08 07; 33(8):1208-1214.
-
Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 2023 05 12; 12(10).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|